

 $R_{esponse} E_{valuation} I_n N_{eurofibromatosis} S_{chwannomatosis} \\ INTERNATIONAL COLLABORATION$

- If sharing any data or information from these slides generated by the REiNS International Collaboration, please acknowledge the authors, group chairs, and specific working group.
- If using any information presented with a citation, please reference the primary source.

Inching toward decentralized trials for NF1 and SWN

Scott Plotkin, MD, PhD Mass General Hospital / Harvard Medical School December 3, 2023



Outline of talk

- Known barriers to clinical trial participation
- Features of NF1-SWN that hinder clinical trial participation
- Rationale for decentralized trials in NF1-SWN
- Completed/ongoing decentralized trials in NF1 and SWN
- Looking forward: a REiNS perspective



Outline of talk

- Known barriers to clinical trial participation
- Features of NF1-SWN that hinder clinical trial participation
- Rationale for decentralized trials in NF1-SWN
- Completed/ongoing decentralized trials in NF1 and SWN
- Looking forward: a REiNS perspective



Barriers to participation in clinical trials

- Contributing factors vary by indication and patient populations
 - Disease-specific (ovarian cancer vs. COVID-19 vs. lupus)
 - Race and ethnicity
 - Gender
 - Geography (rural vs. urban)
 - Age

Selected structural barriers to enrolling cancer patients to clinical trials: Physician and staff perspectives

	Total (n=120) N (%)	Physician (n=47) N (%)	Staff (n=73) N (%)
Administrative			
Difficult to keep track of eligibility	74 (73.3%)	38 (84.4%)	36 (64.3%)
Enrolment process is too time consuming	48 (49.0%)	26 (56.4%)	22 (42.3%)
Patient-related			
Patients refuse placebo	43 (51.8%)	20 (50.0%)	23 (53.5%)
Patients frequently miss appts	35 (35.7%)	14 (32.6%)	21 (38.2%)
Process related			
Communicating complex information very difficult	56 (57.1%)	26 (56.5%)	30 (57.5%)
Making time during visit	47 (50.5%)	31 (67.4%)	16 (34%)
Few eligible patients	45 (46.9%)	22 (51.2%)	23 (43.4%)

Hillyer et al, Clin Trials, 2020



Barriers to enrollment in clinical trials which can also exacerbate inequity


- Cost/financial
 - Working patients may not have the ability to travel, miss work, or to pay for an extra day of parking to participate in clinical trials
 - Persons with annual income below \$50,000 are 27% less likely to participate
- Insurance
 - Insurance may not cover costs associated with clinical trial
 - Patients require assistance with insurance issues which may not be available
- Mistrust of medical research
 - Historical (Tuskegee syphilis trials, 1932-1972)
 - Use of placebo controls
- Health literacy
 - Lack of literacy can leave patients fearful of the unknown

Roy et al, Int J Rad Onc Biol Phys, 2022



Barriers to enrollment in clinical trials which can also exacerbate inequity

- Eligibility criteria are also often used to exclude patients from participation
 - Higher rates of comorbidities can be linked to different social determinants of health
 - Exclusion of patients with psychiatric history can reduce enrollment to pain trials
- Poor knowledge about clinical trials
 - Patient factors:
 - Awareness: 85% of patients are not aware that they could participate in a clinical trial
 - Health literacy: Patients with low health literacy are less likely to enroll
 - Physician factors:
 - **Mismatch** between site of clinical trials (high-resource institutions) and where most patients are seen (community health clinics)
 - Lack of awareness of ongoing clinical trials
 - Perceived lack of time to refer patients






Outline of talk

- Known barriers to clinical trial participation
- Features of NF1-SWN that hinder clinical trial participation
- Rationale for decentralized trials in NF1-SWN
- Completed/ongoing decentralized trials in NF1 and SWN
- Looking forward: a REiNS perspective



Rarity of NF1/SWN limits pool of patients for trials

- Regional prevalence
 - NF1: 1 in 4,088
 - *NF2*-SWN: 1 in 50,500
 - non-*NF2*-SWN: 1 in 126,315
- Birth incidence
 - NF1: 1 in 2,000
 - *NF2*-SWN: 1 in 27,956
 - non-*NF2*-SWN: 1 in 68,956





Few specialty NF clinics in the United States

- NF Clinic Network was created in 2007 by CTF to recognize clinics with expertise in caring for persons with NF1 and SWN
- In 2015, 50 specialty clinics with patient volume 10,245 (13% of estimated NF population)
- Only 43% of patients in CTF Registry receive care at NF specialty clinic
- Travel distances to specialty clinic
 - Average patient travels 50 miles to nearest clinic
 - 25% of patients travel more than 125 miles to nearest clinic
 - Adults travel further than children (300 vs. 68 miles) to high volume clinics
 - SWN patients travel further than NF1 patients (>300 miles vs. 160 miles) to high volume clinics



Merker et al., BMC Health Serv Res, 2018

NF specialty clinics are not evenly distributed across US leading to unequal access to services and clinical trial opportunities



Merker et al., BMC Health Serv Res, 2018



Capacity for specialized NF care varies widely among US regions



Plains: Mideast: Great Lakes: New England: **Rocky Mountains:** Southeast: Southwest: Far West:

1 clinic for 855 patients 1 clinic for 1085 patients 1 clinic for 1136 patients 1 clinic for 1192 patients 1 clinic for 1423 patients 1 clinic for 1814 patients 1 clinic for 3261 patients 1 clinic for 3357 patients

Merker et al., BMC Health Serv Res, 2018



Even fewer centers that offer clinical trials

Ouebed City Montreal NORTH DAKOTA MENTANA NEBRASKA NEVAD Allow Spring lan Francisco **United States** Australia San Jose Las Vegas Nastrolla OKLAHOM NEW MERICO El Paso San Arth

DOD Neurofibromatosis Clinical Trials Consortium

24 sites across US and Australia



Health literacy among NF1-SWN patients at Mass General

- Health literacy is "the degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions"
- Assessed using 2 scales
 - Adapted FCCHL: self-reported perceptions of functional, communicative, and critical health literacy
 - Health LiTT: performance-based health literacy.
- Participants had moderate levels of health literacy by FCCHL
- Lower health literacy scores for
 - Less educated than more educated
 - Learning disability than no learning disability
- Diagnosis, gender, race were not significant predictors

Merker et al., J Neuro-oncol, 2018



Financial issues for NF1 patients

- Many persons with NF1 in Denmark are not employed, mainly due to health reasons
- Reduced disposable income compared to controls (14%)
- Less likely to be employed in high skilled occupations




Fig. 1 Employment (A), unemployment (B), health-related unemployment (C) and low income (D) by ages 30 to 50 years for adults with NF1 and population comparisons

Kenborg et al., Orphanet J Rare Dis, 2023



Summary of features of NF1/SWN that may hinder clinical trial participation and slow progress for new treatments

Patient-related

- Rarity of NF1/SWN
- Reduced SES (disposable income, travel, missed work)
- Insurance coverage
- Reduced health literacy due to learning disability

Structural

- Few specialty clinics, even fewer clinical trial sites
- Restrictive trial eligibility criteria



Outline of talk

- Known barriers to clinical trial participation
- Features of NF1-SWN that hinder clinical trial participation
- Rationale for decentralized trials in NF1-SWN
- Completed/ongoing decentralized trials in NF1 and SWN
- Looking ahead: a REiNS perspective



Rationale for decentralized trials in NF1/SWN

Barrier to trial participation	Potential benefit for decentralized trial		
Rarity of NF1/SWN	Improve accrual by lowering distance and financial barriers		
Reduced SES (disposable income, travel, missed work)	Reduce costs for participants who will travel less frequently to clinic sites		
Insurance coverage	No obvious benefit		
Reduced health literacy due to learning disability	Incorporation of virtual educational tools		
Few specialty clinics, even fewer clinical trial sites	Can open trials to patients not seen as specialty clinics		
Restrictive trial eligibility criteria	Can accommodate more liberal eligibility criteria		



Outline of talk

- Known barriers to clinical trial participation
- Features of NF1-SWN that hinder clinical trial participation
- Rationale for decentralized trials in NF1-SWN
- Completed/ongoing decentralized trials in NF1 and SWN
- Looking forward: a REiNS perspective



A "game changing" clinical trial: SPRINT The National Cancer Institute Model

Children (patient reported outcomes):

- Pain intensity (Numeric Rating Scale; NRS-11)
- Interference of pain in daily functioning (Pain Interference Index; PII)
- Health-related quality of life (QOL; PedsQL Generic Core Scales)
- PROMIS Mobility and Upper Extremity functioning
- Global Impression of Change (GIC) Scale

Parents (observer reported outcomes (ObsRO):

- PII for children ≥5 year
- PedsQL for all ages
- PROMIS Mobility and Upper Extremity functioning
- Global Impression of Change (GIC) Scale

Specific Evaluations Based on PN Location/Morbidity:

Orbital PN

□ Ophthalmologic functional evaluations

Airway PN

Sleep study
 PFTs/Oscillometry
 Endurance evaluation: 6-Minute Walk-Run Test

Motor PN (Lower Extremity)

Strength evaluation
 ROM evaluation
 Leg length evaluation
 Endurance evaluation: 6-Minute Walk-Run Test
 PROMIS

Motor PN (Upper Extremity)

□ Strength evaluation
 □ ROM evaluation
 □ Grooved Pegboard Test (Age ≥5 years)
 □ PROMIS

Bowel/Bladder PN

Bowel/Bladder Questionnaire

Visible PN, Disfigurement (or Potential Disfigurement)

Photography

+/- Video

Other PN

PN affecting speech/swallow: Speech Pathology
 Assessment
 PN affecting auditory system: Audiology and/or ENT



Gross et al., NEJM, 2020

SPRINT trial was partially decentralized (a "hidden" feature of NCI trials to improve participant convenience)

	Table 1. Trial Evaluations.*					
	Evaluation	Category of Plexiform Neurofibroma–Related Complications	Baseline	Time Point after Baseline†		
	Safety and disease evaluations					
*	History taking and physical examination, safety labora- tory studies	All	Yes	Before cycles 2, 3, 4, 5, 7, 9, 11, 13, 17, 21, and 25, then every 6 cycles		
*	Echocardiography, plexiform neurofibroma disease evaluation (MRI)‡	All	Yes	Before cycles 5, 9, 13, 17, 21, and 25, then every 6 cycles		
*	Ophthalmologic examination	All	Yes	Before cycles 5 and 13, then every 12 cycles		
	Patient diary and capsule count	All	No	Before cycles 3, 5, 9, 13, 17, 21, and 25, then every 6 cycles		
	Pharmacokinetics and pharmacodynamics					
	Selumetinib and N-desmethyl selumetinib	All	Yes	Before cycle 2 or 3		
	Cytokines and bone marrow-derived precursor cells	All	Yes	Before cycles 3, 5, 9, and 13 and at the time of progression		

^{*} Some of these evaluations (non-restaging visits) were performed by local providers/local labs throughout the trial

*Some of these evaluations were done by local providers during COVID19 travel restrictions

Gross et al., NEJM, 2020




A missed opportunity: under-enrollment for pain study in SWN

- There is significant unmet need for pain therapies to treat SWN-related pain
 - Chronic pain is a common symptom of schwannomatosis
 - No medications are approved to treat schwannomatosis-related pain
- NCT04163419 is the first therapeutic clinical trial in schwannomatosis-related pain
 - Phase 2 clinical trial at Massachusetts General Hospital (single site)
 - Open during COVID-19 pandemic
 - Investigates safety and efficacy of tanezumab (anti-NGF antibody) for moderate-to-severe non-NF2-SWN pain
- Experience from this clinical trial has helped us identify and address barriers to participation in clinical trials for SWN-related pain



Results of recruitment and enrollment process






Lessons learned from the tanezumab study

Recruitment Process and Barriers Mapping

-	Study Recruitment / Outread Sessment Informed Consent	ch / Formal Screening & Enrollment	
Disease-specific barriers	Study design-related barriers	Drug-specific barriers	
• Rarity of schwannomatosis limits the overall number of subjects identified	• The most common eligibility criteria which prevented subjects from participating was a NRS-11 score of <5	 Safety profile of tanezumab (and anti- NGF class) requires exclusion of subjects with osteoarthritis 	
 Some subjects were ineligible due to challenges confirming their diagnosis of schwannomatosis 	 Use of single center limited subjects' ability to participate due to economic and logistical hurdles (time / travel / financial / pain (associated with travel or participating in study activities) burden) 	Subject Subject Subject Subject ability / Subject ability / Subject Subject Subject Subject Ability / Subject Ability	
	 Requirements to discontinue NSAID use, maintain stable dosing of other pain medications, and relatively short duration of treatment with tanezumab influenced some participants' decision to not participate 		



STARFISH is a partially decentralized trials for SWN pain



Clinicaltrials.gov NCT05684692





Original Investigation | Neurology Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis A Fully Remote Randomized Clinical Trial

Ana-Maria Vranceanu, PhD; Heena R. Manglani, PhD; Nathaniel R. Choukas, BS; Millan R. Kanaya, BS; Ethan Lester, PhD; Emily L. Zale, PhD; Scott R. Plotkin, MD, PhD; Justin Jordan, MD, MPH; Eric Macklin, PhD; Jafar Bakhshaie, MD, PhD


- 993 patients responded to flyer → 371 screened (37%) → 286 eligible (28%) → 228 signed informed consent (23%)
- Intervention: 8 weekly virtual group session, 90 min each, with instruction using 3RP-NF or active control
- Primary outcome: Physical health and psychological QOL



Results

- 228 participants
- 166 (73%) with NF1
- 32 (14%) with NF2-SWN
- 30 (13%) with non-*NF2*-SWN
- 217 (95%) attended 6 or more of 8 sessions and provided posttest data

→ Successful completion of fully decentralized psychosocial trial in NF1-SWN



Changes in mean scores at baseline, after treatment, and at 6- and 12-month follow-up. 3RP-NF indicates Relaxation Response Resiliency Program for Neurofibromatosis; HEP-NF, Health Enhancement Program for Neurofibromatosis.



Outline of talk

- Known barriers to clinical trial participation
- Features of NF1-SWN that hinder clinical trial participation
- Rationale for decentralized trials in NF1-SWN
- Completed/ongoing decentralized trials in NF1 and SWN
- Looking forward: a REiNS perspective



Inching toward (partially) decentralized trials in NF1-SWN

- Not all trials should be fully decentralized
 - Trials with investigational agents (unapproved drugs)
 - Trials of approved drugs with IV formulation, narrow risk/benefit profile
 - Build on success of NCI model (SPRINT trial)
- During trial design, consider:
 - What type of decentralization would improve recruitment (faster, more diverse), reduce costs, improve participant convenience?
 - Are virtual tools/endpoints currently available for NF1-SWN?
 - Can virtual tools/endpoints available for other conditions be adapted?
 - Can we convert current REiNS endpoints to virtual tools/endpoints?
- Next steps for REiNS
 - Working groups to adapt or create virtual endpoints for trial use



Acknowledgements

Massachusetts General Hospital

Vanessa L. Merker, PhD Jennifer Da Danielle Silverman, MS Justin T. Jordan, MD, MPH K. Ina Ly, MD Alona Muzikansky, MA Michael Parsons, PhD Lei Xu, MD, PhD Scott R. Plotkin, MD, PhD Ana-Maria Vranceanu, PhD

National Cancer Institute

Andrea Gross, MD Brigitte Widemann, MD Pamela Wolters, PhD

Pfizer

Mark Brown, MD Scot Styren, PhD



The case for decentralized trials in NF1/SWN

- Rare
- Few clinics, not evenly distributed
- Low diversity
- Access to trials is unfair (certain parts of the country)
- Cost –
- We are a roll model for rare diseases
- Affects everyone evenly
- Heterogenous manifestations too burdensome to do this in clinic. NIH can do this but not everyone else.
- Many outcomes besides tumor size that are important see STARfISH and ANA-MARIA trial.
- The road to partial decentralization



Future of decentralized trials in NF1/SWN

- Partial decentralization bloods, imaging, PROs, central review
- Maybe good for natural history, for pregnant women/children (difficulty to travel)
- Good for equity, faster enrollment
- Can do more frequent sampling (high density data)
- Lead with PRO > functional > others
- Major challenges
 - Participant drop out
 - Missing data
- What are questions I want answered?



Opportunities to address these issues with DCT

- In addition, follow-ups needed for clinical trials can be performed while patients attend regular appointments, eliminating the need for extra visits.
- These measures can address socioeconomic barriers such as transportation costs and loss of income due to repeated leave from work.
- When clinical trial staff work alongside community clinic physicians, this reduces the extra burdens associated with referrals on physicians.
- Thus, this practice increases physician referral rates of the population of interes



What do (French) patients want?

- Involve local hospitals and health care providers for follow-up visits.
- Involve primary care doctors for informed consent and follow-up visits.
- Ensure close contact with investigators.
- Provide equipment (technology) suitable to patients' conditions.
- Apply technology to reduce the burden of data collection.



Nguyen, J. Med Internet Res, 2022